Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned an average recommendation of “Buy” from the twenty-five ratings firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $72.50.

A number of equities research analysts recently weighed in on DXCM shares. Northland Securities cut DexCom from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $85.00 to $60.00 in a report on Thursday, September 28th. Wedbush restated a “buy” rating and issued a $76.00 price target on shares of DexCom in a report on Wednesday, October 4th. Zacks Investment Research lowered DexCom from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. Morgan Stanley reduced their target price on DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. Finally, TheStreet lowered DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th.

Shares of DexCom (NASDAQ DXCM) opened at $56.75 on Monday. The firm has a market capitalization of $4,931.75, a P/E ratio of -99.56 and a beta of 0.31. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom has a fifty-two week low of $42.62 and a fifty-two week high of $88.80.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.11. DexCom had a negative return on equity of 20.44% and a negative net margin of 7.21%. analysts expect that DexCom will post -0.64 earnings per share for the current year.

In other DexCom news, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total transaction of $73,280.70. Following the transaction, the executive vice president now owns 65,049 shares of the company’s stock, valued at approximately $2,915,496.18. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 12,000 shares of the stock in a transaction on Monday, November 20th. The stock was sold at an average price of $55.00, for a total value of $660,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,140 shares of company stock worth $2,158,576. Corporate insiders own 1.70% of the company’s stock.

Several institutional investors have recently modified their holdings of DXCM. The Manufacturers Life Insurance Company raised its position in shares of DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after buying an additional 354 shares during the period. Ithaka Group LLC raised its position in shares of DexCom by 0.9% in the 2nd quarter. Ithaka Group LLC now owns 81,416 shares of the medical device company’s stock worth $5,956,000 after buying an additional 703 shares during the period. Advisor Group Inc. raised its position in shares of DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares during the period. Dimensional Fund Advisors LP raised its position in shares of DexCom by 0.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 127,769 shares of the medical device company’s stock worth $6,247,000 after buying an additional 1,095 shares during the period. Finally, Stifel Financial Corp raised its position in shares of DexCom by 15.2% in the 3rd quarter. Stifel Financial Corp now owns 8,567 shares of the medical device company’s stock worth $422,000 after buying an additional 1,129 shares during the period.

COPYRIGHT VIOLATION NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/15/dexcom-inc-dxcm-receives-consensus-rating-of-buy-from-analysts.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.